Scripps Research, page-27

Oak

here is an update from yesterday of Molnupiravir with it's full history. Worth noting the following about it's 'failure' for hospitalized cases of C19.
Hopefully though, its ongoing trials for earlier onset cases will prove more successful.

It's mode of action is very different to viroporin inhibition.

Molnupiravir (MK-4482, EIDD-2801) Antiviral Clinical TrialsThe companies announced on April 15, 2021, based on a planned interim analysis of data from Phase 2, the dose-finding portion (Part 1) of two ongoing placebo-controlled Phase 2/3 trials evaluating molnupiravir administered twice a day for five days in outpatients (MOVe-OUT) and hospitalized patients (MOVe-IN) with COVID-19, and from a previously completed Phase 2a dose-ranging study in outpatients, the decision has been made to proceed with the Phase 3 portion (Part 2) of MOVe-OUT in outpatients with COVID-19, evaluating the 800 mg dose of molnupiravir twice daily. Data from MOVe-IN indicate that molnupiravir is unlikely to demonstrate a clinical benefit in hospitalized patients, who generally had a longer duration of symptoms before study entry; therefore, the decision has been made not to proceed to Phase 3.
Molnupiravir (MK-4482, EIDD-2801) Antiviral